Sulfamethoxazole/Trimethoprim

Antimicrobial Activity

Gram-positive pathogens – Staphylococcus aureus (MSSA, MRSA), Listeria monocytogenes Gram-negative pathogens – Enterobacteriaceae, Stenotrophomonas maltophilia Fungal and parasitic pathogens – Pneumocystis jirovecii and Toxoplasma qondii

Dosing



Weight based dosing of SMX/TMP refers to the Trimethoprim component

Available Formulations

PO	Double Strength (DS) tablet Single Strength (SS) tablet Oral suspension	Sulfamethoxazole 800 mg/Trimethoprim 160 mg Sulfamethoxazole 400 mg/Trimethoprim 80 mg Sulfamethoxazole 40 mg/Trimethoprim 8 mg (per 1 mL)	20 mL equals 1 DS tablet
IV	Injectable vial	Sulfamethoxazole 80 mg/Trimethoprim 16 mg (per 1 mL)	10 mL equals 1 DS tablet

Dosing Regimens

Most infections 5-10 mg/kg/day* divided q6-12h

Severe infections 15-20 mg/kg/day* divided q6-12h

Indication-specific dosing	IV Dosing*	PO Dosing [†]
Source of infection	1	
Respiratory tract infections (non-P.jirovecii) 10-15 mg/kg/day divided q8-12h	2 DS tabs BID-TID
Skin & soft tissue infections	5 5-10 mg/kg/day divided q12h	1-2 DS tabs BID
GU tract infections (i.e. UTI, pyelonephritis) 5 mg/kg/day divided q12h	1 DS tab BID
Pathogen directed therapy	/	
Pneumocystis jirovecii Treatmen Prophylaxi:		2 DS tabs TID 1 DS tab 3x/week [‡]
Nocardia spp	. 15 mg/kg/day divided q6-12h	2 DS tabs TID
Toxoplasma gondi	i 10 mg/kg/day divided q12h	2 DS tabs BID
Listeria monocytogene	s 20 mg/kg/day divided q6-12h	2 DS tabs QID
Stenotrophomonas maltophilic	a 10-15 mg/kg/day divided q8h	2 DS tabs TID

^{*} Dosing based on actual body weight. In obese patients, adjusted body weight can be considered at higher doses (e.g. ≥ 10mg/kg)

Renal Adjustment

Creatinine Clearance (mL/min)

	10-29	<10 HD	CRRT
Treatment of PJP (i.e. 15-20 mg/kg/day g6-8h)	10 mg/kg/day divided q12h	5-10 mg/kg/day divided q12-24h	10-15 mg/kg/day divided q6-8h
Serious Infections (i.e. 10-15 mg/kg/day q8-12h)	50% daily dose reduction	Not recommended – Consider alternative agents. If safer options unavailable, refer to dosing below:	
SSTI & GU infections (i.e. 5-10 mg/kg/day q12h)	with same frequency	5 mg/kg/day divided q24h	5-10 mg/kg/day divided q12h

Precautions

SMX/TMP should be avoided in the following patient groups:

- Patients with **G6PD** deficiency due to the increased risk of hemolysis
- Pregnant patients in their 1st trimester and 3rd trimester (i.e. near term)
- Breastfeeding patients nursing premature infants or neonates with hyperbilirubinemia or G6PD deficiency



The information contained in these pages is intended for use by William Osler Health System staff. Clinical recommendations serve to guide therapeutic decision making, and should be used in conjunction with clinical assessment. Clinical content found in these documents have been reviewed & approved by the Antimicrobial Subcommittee.

[†] Oral dose is an extrapolation based on weight based IV dosing, assuming 70 kg patient

[‡] Various prophylactic regimens exist (including 1 DS tab daily, and 1 SS tab PO daily)